ARMP
Armata Pharmaceuticals Inc
3.70$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 32.4% | 19.5% | 34.7% | 28.5% | 22.8% | 13.1% | 15.1% | 9.3% | 18.9% | 13.9% | 8.5% | 30.2% | |
| 21.2% | 13.7% | 31.5% | 24.4% | 17.4% | 10.7% | 13.4% | 5.4% | 16.5% | 11.3% | 6.8% | 26.6% | |
| 21.2% | 13.7% | 31.5% | 24.4% | 17.4% | 10.7% | 13.4% | 5.4% | 16.5% | 11.3% | 6.8% | 26.6% | |
| 7.5% | 3.4% | 1.4% | 1.1% | 2.3% | 0.9% | 0.3% | 2.7% | 0.8% | 0.6% | 0.1% | 2.8% | |
| – | – | -1.4% | – | – | – | – | – | – | – | – | – | |
| 3.1% | 3.5% | 2.9% | 3.2% | 3.6% | 4.0% | 4.0% | 4.3% | 3.9% | 4.5% | 5.0% | 3.9% | |
| 9.1% | 10.4% | 8.5% | 9.5% | 10.4% | 11.9% | 11.8% | 12.7% | 11.5% | 13.3% | 14.7% | 11.4% | |
| 111.0% | 132.6% | 147.0% | 142.6% | 151.9% | 155.6% | 161.6% | 186.0% | 206.8% | 384.3% | 546.4% | 357.0% | |
| 19.4% | 16.7% | 91.4% | 113.7% | 120.3% | 55.8% | 126.7% | 148.6% | 156.3% | 11.6% | 13.2% | 278.2% | |
| 11.9% | 9.6% | 86.5% | 108.9% | 114.4% | 50.2% | 122.9% | 144.6% | 151.5% | 5.9% | 6.6% | 273.6% | |
| 3.3% | 1.6% | 1.7% | 1.6% | 1.8% | 0.9% | 1.1% | 1.2% | 1.4% | 1.2% | 0.9% | 1.3% | |
| 63.9% | 83.7% | 29.4% | – | – | 64.1% | – | – | 17.0% | 334.2% | 491.3% | – | |
| -11.0% | -32.6% | -47.0% | -42.6% | -51.9% | -55.6% | -61.6% | -86.0% | -106.8% | -284.3% | -446.4% | -257.0% | |
| -256.3% | -314.0% | -277.4% | -299.9% | -336.3% | -379.2% | -383.1% | -433.9% | -421.4% | -652.3% | -883.8% | -603.4% | |
| 32.0% | 36.7% | 30.0% | 53.8% | 36.8% | 68.4% | 41.5% | 44.8% | 40.5% | 47.3% | 52.3% | 69.0% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.